心臓外科手術を受けた患者におけるウォルファリンの用量アルゴリズム: システムレビュー
G Svyatova1, G Berezina2, A Murtazaliyeva1
11Scientific and Educational Center, Center for Molecular Medicine, Almaty, Kazakhstan.
Georgian medical news
|August 30, 2025
まとめ
薬物遺伝的アルゴリズムを用いた個別化されたワルファリンの投与は,治療結果を大幅に改善し,心臓手術患者の出血を減少させます. 遺伝子型による治療は,ワーファリンの管理を強化し,INRの安定性と臨床結果の改善につながります.
科学分野:
- 薬剤遺伝学
- 心血管外科
- ファルマゲノミクス
背景:
- 心臓外科手術患者のワーファリンの投与は複雑で,個体間では有意な変動がある.
- 標準的な投与は,しばしば低最適の抗凝固作用と出血や血栓形成のリスクを高めます.
- 特にCYP2C9およびVKORC1遺伝子の薬剤遺伝的変異は,ワーファリンの代謝と有効性に影響する.
研究 の 目的:
- パーソナライズされたワーファリン治療の臨床的結果,安全性,適用を体系的に評価する.
- 心臓外科手術の患者に用いる薬剤遺伝的なワルファリン投与アルゴリズムの有効性を評価する.
- 治療範囲 (TTR),出血事件,およびINRの安定性に対する遺伝子型による投与の影響を決定する.
主な方法:
- 2015年1月から2025年3月までの間に発表された17の研究を体系的にレビューした.
- 対象となった研究は,心臓手術患者のCYP2C9とVKORC1の多形性を含むワーファリン投与アルゴリズムに焦点を当てた.
- 主な評価対象は,TTR,出血発生率 (BER),INRの安定性でした. データベースの検索には,Scopus,Web of Science,PubMed,Cochraneが含まれていました.
主要な成果:
- ゲノタイプ別ワルファリン投与はTTRの改善を示し,ベイジアンモデルは63% (NextDose) と56% (標準投与) を示した.
- 遺伝子型によるアプローチにより,出血が著しく減少し (34 件から 16 件),INRの安定性が向上した (83. 1% から 86. 1%).
- ゲノタイプによるワルファリン投与は,標準投与の57. 43%と比較してTTRが77. 76%に達し,投与精度が向上したことを示した.
結論:
- 遺伝子型データは,正確なワルファリン投与,TTR,INR制御の改善,心臓手術患者の出血リスクを減らすために臨床的に重要です.
- 薬剤遺伝的アルゴリズムは心臓手術後のワーファリン管理に より効果的なアプローチを提供します.
- アルゴリズムを最適化し,遺伝子パネルを拡張し,特定の患者集団に合わせたアプローチを行うにはさらなる研究が必要です.
関連する概念動画
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K


